Overall, our work identifies the cellular origin and molecular mechanism of BDTT, indicating that harnessing BMI1-miR-213-1-3p-CTSB signaling axis could be a potential therapeutic approach for HCC patients with BDTT. Here, BMI1 is linked to hepatocellular carcinoma.